Insulin Overpricing

DEFENDANT NAME: Sanofi U.S., Novo Nordisk Inc., Eli Lilly and Company
STOCK SYMBOL:
CASE NUMBER: 3:17-cv-00699
CASE NAME:
COURT: U.S. District Court for the District of New Jersey
STATUS: Active
CLASS PERIOD:
LEAD PLAINTIFF DEADLINE:
DATE FILED: 02/02/17
COURT LOCATION:
RELATED DOCUMENTS:
CONTACT:
888-381-2889 insulin@hbsslaw.com

INSULIN PURCHASERS

Attorneys are currently looking for people who purchased Lantus, Levemir, Novolog, Humalog and Apidra from the following states: Alaska, Alabama, D.C., Hawaii, Minnesota, Missouri, New Hampshire, North Carolina, North Dakota, Oklahoma, Rhode Island, South Carolina, South Dakota, Virginia, West Virginia or Wyoming.

Did you purchase Humalog in Arkansas, Illinois, Kentucky, Mississippi, New Mexico, Oregon, Tennessee or Vermont?

Did you purchase Novolog or Levemir in Colorado, Montana, Nevada, or Washington?

Did you purchase Lantus, Apidra or Toujeo in Louisiana, Maine, Mississippi, Tennessee or Washington?
 

Do you have type 1 or type 2 diabetes?
Did you pay high out-of-pocket costs for Lantus, Levemir, Novolog, Humalog, Apidra, Basaglar, Fiasp and/or Toujeo in the past 4 years because you are uninsured, have a high-deductible plan, or have a plan with high coinsurance rates?

Insulin manufacturers have fraudulently increased prices. Find out your rights »

Insulin Overpricing Infographic

Hagens Berman has filed a nationwide class-action lawsuit against drug manufacturers, Sanofi, Novo Nordisk and Eli Lilly, for committing fraud and illegally raising the price of insulin for many of the 29 million people in the U.S.  living with diabetes.

The firm’s investigation shows that these companies have increased the publicly reported, list prices of Lantus, Levemir, Novolog, Apidra, and Toujeo by more than 160% in the last five years, while keeping the prices they offer to pharmacy benefit managers constant or even lowering them.

If you are, or were at one time, uninsured and paying out-of-pocket for Lantus, Levemir, Novolog, Apidra, Basaglar, Fiasp and/or Toujeo or are insured, but paying significant amounts out-of-pocket under a high-deductible plan or a plan with high coinsurance rates, you may be entitled to damages. The firm is also interested in hearing from individuals who did not purchase Lantus, Levemir, Novolog, Apidra, Basaglar, Fiasp and/or Toujeo, but would have if the prices of these drugs had been lower.

ATTORNEYS SEEKING THOSE AFFECTED

  • Attorneys are currently looking for people in high deductible plans, in Medicare Part D plans, in plans with high co-insurance rates, or people who are uninsured who purchased Humalog, Basaglar, Lantus, Apidra, Toujeo, Fiasp, Tresiba, Novolog and Levemir based on list prices in following states: Alaska, Alabama, D.C., Hawaii, Nevada, New Hampshire, Rhode Island, South Carolina, South Dakota, Vermont, Virginia, West Virginia or Wyoming. Sign up here.
  • Did you purchase Humalog in in North Carolina or New York? Sign up here.
  • Did you purchase Fiasp, Novolog, Tresiba, or Levemir in Louisiana or Missouri? Sign up here.
  • Did you purchase Lantus, Apidra or Toujeo in Maryland? Sign up here.

DRUG-PRICING fraud EXPLAINED

In recent years, Big Pharma has sought to exponentially increase its profits on drugs that keep people alive, raising costs to consumers that are unrelated to any increase in production or research and development costs. Insulin has been a prime money-maker for Big Pharma.

In the drug pricing and distribution system, drug manufacturers often offer slightly lower prices to pharmacy benefit managers. However, in the case of Lantus, Levemir, Novolog, Apidra, Basaglar, Fiasp and Toujeo, the difference between the drugs’ list prices and the prices offered to pharmacy benefit managers is enormous. Pharmacy benefit managers profit from these discrepancies in prices.

Hagens Berman believes that as the list prices of Lantus, Levemir, Novolog, Apidra, Basaglar, Fiasp and Toujeo move further and further away from the real prices offered to pharmacy benefit managers, these list prices become so misrepresentative, they are fraudulent.

your consumer rights

The lawsuit seeks reimbursement for the fraudulent activities carried out by some of the largest makers of analog insulin drug products – Sanofi, Novo Nordisk and Eli Lilly.

Hagens Berman believes action must be taken for the millions of people living with diabetes who are forced to pay fraudulently high prices for analog insulins or else forgo purchase of these medications at the whim of Big Pharma.

TOP consumer rights FIRM

Hagens Berman is one of the most successful litigation law firms in the U.S. and has achieved more than $260 billion in settlements against Big Pharma, tobacco companies, automakers, big banks and others. Your claim will be handled by attorneys experienced in consumer and pharmaceutical law.

NO COST TO YOU

There is no cost or fee whatsoever involved in joining this case. In the event Hagens Berman or any other firm obtains a settlement that provides benefits to class members, the court will decide a reasonable fee to be awarded to the class' legal team. In no case will any class member ever be asked to pay any out-of-pocket sum.


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Contact Us:

Hagens Berman is a national law firm that purchases ads. Submitting this form does not create an attorney-client relationship with the firm, but we will make our best effort to keep your information confidential.

 

 

Case videos

Case Gallery

Case Timeline

02/20/19: INSULIN PURCHASERS

Attorneys are currently looking for people who purchased Lantus, Levemir, Novolog, Humalog and Apidra from the following states: Alaska, Alabama, D.C., Hawaii, Minnesota, Missouri, New Hampshire, North Carolina, North Dakota, Oklahoma, Rhode Island, South Carolina, South Dakota, Virginia, West Virginia or Wyoming.

Did you purchase Humalog in Arkansas, Illinois, Kentucky, Mississippi, New Mexico, Oregon, Tennessee or Vermont?

Did you purchase Novolog or Levemir in Colorado, Montana, Nevada, or Washington?

Did you purchase Lantus, Apidra or Toujeo in Louisiana, Maine, Mississippi, Tennessee or Washington?
 

04/06/18: Amended Complaint Filed

Hagens Berman Files Amended Complaint more »

09/18/17: Steve Berman Named Lead Counsel

02/07/17: Case Transfer

Hagens Berman Sobol Shapiro transferred the Insulin Class Action on behalf of patients paying high out-of-pocket costs for analog insulin to the District of New Jersey from the District of Massachusetts because there was a related case ongoing in the District of New Jersey. Efficiency concerns led us to transfer the case from the District of Massachusetts to that of New Jersey. Absent such a move it is likely the case would have been subject to an MDL petition, which would have slowed the case’s progress.

James Cecchi, of Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C., filed a related suit on behalf of an investor class against Novo Nordisk in New Jersey. James Cecchi remains as one of the lawyers in that suit. There will be a lead counsel selection process pursuant to the federal law governing securities cases in that lawsuit. Hagens Berman Sobol and Shapiro is not involved in that investor class lawsuit.

Hagens Berman Sobol Shapiro is proposed lead counsel for the patient-plaintiff class. We will continue to represent only this patient class, and advocate in the best interests of this class only. As of right now, James Cecchi is local counsel for the patient-plaintiff class. However, because Hagens Berman Sobol Shapiro is lead counsel, our firm will be directing the course of this litigation. We will do so in the best interests of the patient-plaintiff class, and that class only.

01/30/17: Case Filed